|

Dapagliflozin 10 mg Clinical Trials

8 actively recruiting trials

No change since May 2026

Also known as: BR3006A, FARXIGA, Farxiga

Pipeline

Phase 1: 2Phase 2: 3Phase 3: 2Phase 4: 1

Top Sponsors

  • Boryung Pharmaceutical Co., Ltd2
  • University of Campinas, Brazil1
  • University Medical Centre Ljubljana1
  • University Health Network, Toronto1
  • Tor Biering-Sørensen1

Indications

Other8 trials

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
Phase 4
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
Phase 1
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)
Phase 1
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Phase 3
Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
Phase 3
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD
Phase 2
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
Phase 2
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.